After a totally crazy last week, I must say it’s a tremendous relief to get back to focusing on science and early stage clinical development!
Behind the all the ongoing political and Covid-19 furore, the ASH abstracts dropped unexpectedly early on November 4th instead of Bonfire Night and this week it’s the start of the SITC meeting with live presentations already starting.
Every year we post a series of Previews highlighting key data to watch out for on key selected topics. The focus varies with each meeting with a look at different targets, modalities, or tumour types. This year we’re kicking off our coverage with a focused look at bispecific antibodies in early development…
Are bispecifics flying high at ASH20?
To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the ASH meeting — including our first meeting Preview of 2020, subscribers can log-in or you can click to gain access to BSB Premium Content.
While many observers attentions have recently been focused on immuno-oncology of late, particularly with respect to checkpoint blockade and CAR T cell therapies, these are not the only class of drugs that are being investigated in the clinic.
Field of dreams or crowded marketplace?
We saw a lot of early preclinical data and especially got to see quite a few new targets at AACR, while next month ASCO offers a new opportunity to see inital phase 1 data presented in several developmental therapeutic sessions and in the poster halls.
There is no doubt that the oncology R&D niche is becoming increasingly competitive and crowded, which means that companies need to think carefully about how they can clearly differentiate themselves and position their platform much more assertively than before.
For small biotechs, this also means going beyond offering great preclinical packages to demonstrating proof of concept in the clinic, hence phase 1/2 trials are receiving a lot more attention these days, as potential collaborators and acquirers flock to the poster halls.
Today we have a CEO from one of these emerging biotech companies in the BSB hotseat with a candid discussion about their approach, why they are different, and importantly, where they are heading…
To learn more and get a heads up on our latest thought leader interviews and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.